The objective of this study was to assess the correlation between mismatch repair (MMR) status, disease recurrence patterns, and recurrence-free survival (RFS) in patients with high-intermediate-risk (HIR) endometrioid endometrial cancer (EEC). METHODS: A single-institution chart review for consecutive patients who were diagnosed with ECC between 2007 and 2016 was undertaken. Tumor MMR status was determined for all patients based on reported findings for mutL homolog 1 (MLH1), postmeiotic segregation (PMS2), mutS homolog 2 (MSH2), and MSH6 immunohistochemistry; and defective MMR (dMMR) status was defined as the lack of expression of at least 1 of these proteins. Patients were classified with HIR EEC according to criteria used for Gynecologic Oncology Group study 249. The factors associated with recurrence were assessed by logistic regression. RFS and associated factors were assessed by Kaplan-Meier survival analysis and Cox proportional-hazards models. RESULTS: In total, 197 patients who had HIR EEC (64 with dMMR and 133 with intact MMR [iMMR]) were identified, of whom 32 (16.2%) developed recurrent disease. The median follow-up was 54 months. The recurrence rate for women who had dMMR was 28% compared with 10.5% for those who had iMMR (P = .002), independent of the type of adjuvant therapy they received. The increase in distant recurrences among patients who had dMMR was even more pronounced (14.1% vs 3%; P = .003). The estimated 5-year RFS was 66% for women who had dMMR compared with 89% for those who had iMMR (P = .001). Excluding isolated vaginal recurrences, the difference in 5-year RFS was 73.5% versus 95%, respectively (P = .0004). CONCLUSIONS: Patients who had HIR EEC with dMMR had increased rates of recurrence and decreased RFS compared with those who had HIR EEC with iMMR, despite the receipt of similar adjuvant treatment. The current findings highlight the need for alternative treatment options and the importance of MMR status as a biomarker for patients with HIR EEC. Cancer 2019;125:398-405.
INTRODUCTION
Endometrial cancer (EC) is the most common gynecologic malignancy in the United States, with an estimated 63,230 new cases and 11,350 deaths expected in 2018. 1 At the time of diagnosis, greater than 70% of ECs are stage I, and the reported 5-year survival rate is 90%. 2 Although patients with early stage EC have good outcomes overall, a subgroup with so-called high-intermediaterisk (HIR) ECs has been identified in which the local and distant recurrence rates are relatively high. [3] [4] [5] The HIR subgroup is limited to endometrioid cancers and is characterized by older age, deep myometrial invasion, lymphovascular space invasion (LVSI), and higher grade tumors. In an attempt to improve outcomes for women with HIR cancers, in Gynecologic Oncology Group (GOG) Study 249 (GOG249), pelvic radiation (external-beam radiation therapy [EBRT] ) was compared with 3 cycles of chemotherapy plus carboplatin/paclitaxel and vaginal brachytherapy (VBT) among women who had stage I/II HIR EC. 6 Similar 3-year recurrence-free survival (RFS) (82% for both arms) and 3-year overall survival (OS) (91% for the EBRT arm and 88% for the chemotherapy/[VBT] arm) were reported. The vaginal recurrence rate in the GOG249 study was 2.5%; however, the distant recurrence rate at 5 years was 18% in both arms despite what would be considered moderately aggressive primary treatment. 6 Similar findings were noted in the Postoperative Radiation Therapy in Endometrial Carcinoma (PORTEC)-3 trial, in which the 5-year RFS and OS rates were 79% and 83%, respectively, for patients with stage I/II disease. 7, 8 Because the recurrence rates were relatively high in all arms, those 2 studies emphasized the urgent need for a biomarker(s) to improve the identification of patients who are at the highest risk of recurrence and who would benefit most from adjuvant therapy.
Cancer February 1, 2019 Loss of DNA mismatch repair (MMR) is a frequent event in EC. Germline mutations in MMR are observed in approximately 4% of patients with EC; thus, these women have Lynch syndrome (LS) and also have greatly increase risk for colorectal cancer (CRC) and other cancers. 9 Somatic MMR defects are much more common in EC and are identified in approximately 25% of patients, which is substantially higher that the rate of approximately 15% in those with sporadic CRC. 10, 11 In CRC, MMR status is prognostic: patients who have MMR defects have an overall favorable prognosis compared with those who have normal MMR. 12, 13 In EC, the clinicopathologic significance of tumor MMR status is unclear, particularly among women who have early stage disease.
An analysis of endometrioid ECs (EECs) from the NRG Oncology (NRG)/GOG Study 210 (NRG/ GOG210) demonstrated that MMR deficiency was associated with more aggressive tumor characteristics, such as higher stage, higher grade, and LVSI. 10 Progression-free survival (PFS) was lower for women who had defective MMR (dMMR) compared with those who had intact MMR (iMMR) (hazard ratio [HR], 1.37; 95% confidence interval [CI], 1.00-1.86; P < .05). Most recently, Cosgrove and colleagues 14 further refined the association between dMMR and outcomes. Patients who had EC with dMMR associated with the absence of MLH1 expression and methylation of the MLH1 promoter (so-called epigenetic MMR defects) had larger tumors, deeper invasion, and more frequent LVSI. In addition, a higher recurrence rate was noted in patients who had advanced EC with an epigenetic MMR defect compared with those who had EC with iMMR (47% vs 3.4%, respectively). 14 The objective of the current study was to assess the correlation between MMR status, recurrence patterns, and RFS in patients with HIR EC. We also sought to explore differences in response to adjuvant treatment according to MMR status.
MATERIALS AND METHODS

Patient Population
A review of consecutive patients who were diagnosed with EC at The Ohio State University Comprehensive Cancer Center from 2007 to 2016 was undertaken after Institutional Review Board (IRB) approval was obtained. Patients underwent surgical staging with hysterectomy, bilateral salpingo-oophorectomy, and lymph node assessment. Subjects with endometrioid or mucinous histology were classified with HIR according to GOG249 criteria. This classification includes risk factors (grade 2 or 3 tumor, the presence of LVSI, ≥50% myometrial invasion) and age. Patients were considered to meet HIR criteria if they were: 1) age ≥70 years with 1 risk factor; 2) age ≥50 years with 2 risk factors, and 3) age ≥18 years with 3 risk factors. Women who had serous, clear cell, or mixed histology, as well as those with concurrent ovarian pathology and those without available MMR data, were excluded. Adjuvant therapy was at the discretion of the treating physician.
Mismatch Repair Status
Starting in 2006, MMR testing by immunohistochemistry (IHC) was routinely performed (standard of care) for all patients with EC as part of universal screening for LS. Tumor MMR status was determined based on reported findings for MLH1, PMS2, MSH2, and MSH6 IHC; dMMR was defined as a lack of expression of at least 1 of these proteins, as previously described.
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Statistics
Demographic, clinical, pathologic, and follow-up data were abstracted from clinical charts. All statistical analyses were performed with the STATA software package (version 15.0; StataCorp, College Station, TX). Correlations between MMR status and demographic and clinical features were assessed using chi-square tests and t tests. Multivariable logistic regression models were developed, and odds ratios (ORs) were used to evaluate the risk factors associated with recurrence. The following predictor variables were considered: MMR status (dMMR, iMMR), age at the time of surgery, body mass index (BMI) (<30 kg/m 2 , 30-35 kg/m 2 , >35 kg/m 2 ), surgical stage (IA, IB, II), myometrial invasion (<50% invasion, ≥50% invasion), the presence or absence of LVSI, tumor grade, 1-3 adjuvant therapy (no adjuvant therapy [NAT], VBT, EBRT, chemotherapy), and whether any form of radiation therapy was received. Patients who received chemotherapy and either VBT or EBRT were categorized as chemotherapy recipients. MMR status was assessed first in a univariable logistic regression model. Simple multivariable logistic regression models containing only MMR status and 1 other predictor were then considered. Finally, any variables with a significance level of P < .25 were evaluated in further multivariable regression models. Confounding was defined by a change >15% in the coefficient of MMR status. Interaction terms with MMR status were included at a significance level of P < .10. Backward selection was used to determine a final multivariable model by removing factors at a significance level of P > .05.
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Survival estimates comparing patients with dMMR versus those with iMMR were determined using Kaplan-Meier survival analysis, and significance was assessed using the log-rank test. RFS was defined as the time from surgery to recurrence; patients who did not develop recurrent disease were censored at the time of their last encounter with any physician or after 120 months, whichever came first. The factors associated with reduced RFS were assessed using Cox proportional-hazards models and were evaluated with HRs. The same predictor variables were considered, with the exception of the percentage of myometrial invasion, which was evaluated as a continuous variable in this model rather than a binary variable. The assumption of proportional hazards was assessed for each variable. Again, MMR status was assessed first in a univariable Cox proportional-hazards model. Simple multivariable Cox proportional-hazards models containing only MMR status and 1 other predictor were then considered. Finally, any variables with a significance level of P < .25 were evaluated in further Cox proportional-hazards models. Backward selection was used to determine a final multivariable model by removing factors at a significance level of P > .05.
RESULTS
In total, 248 patients met HIR criteria. MMR IHC data were unavailable for 47 patients. Four additional patients were excluded because of synchronous ovarian cancer, leaving 197 evaluable patients. Ninety-eight percent of patients were white. In total, 173 patients (88%) underwent lymph node dissection. The median follow-up was 54 months. Sixty-four of 197 patients (32.5%) were classified with dMMR, and 133 (67.5%) were classified with iMMR.
Patient characteristics stratified by MMR status are provided in Table 1 . Age at diagnosis, BMI, and adjuvant therapy were similar for the dMMR and iMMR groups. Women with iMMR tumors tended to have more frequent deep myometrial invasion (>50%) than those with dMMR tumors (70.7% vs 57.8%; P = .07). In addition, women with iMMR tumors were significantly more likely to have stage II disease (27.8%) than those with dMMR tumors (9.4%; P < .0001). Conversely, higher tumor grade was associated with dMMR (81.2% of women with dMMR had grade 2 or 3 tumors vs only 55.6% of those with iMMR; P < .0001).
Fifty-five percent of patients received no adjuvant therapy, 53 (27%) received VBT, 15 (7.6%) received EBRT, and 21 (10.7%) received chemotherapy. Adjuvant therapy was similar between patients with dMMR and iMMR (P = .837) ( Table 1) .
Recurrence Patterns
Thirty-two patients (16.2%) experienced recurrent disease. There were more locoregional recurrences than distant recurrences (19 and 13 recurrences, respectively), and the (total) recurrence rate was significantly higher among patients with dMMR that among those with iMMR (28% vs 10.5%; P = .002). The rate of recurrence was higher for patients with dMMR across all types of adjuvant therapy or observation (Table 2 ). Most striking was the increased rate of distant recurrences among patients with dMMR (14.1% vs 3% for the iMMR group; P = .003).
Factors Associated With Recurrence
Multivariable logistic regression models that included MMR status and a single other variable revealed there Cancer February 1, 2019 was no evidence for an association between age, the presence of LVSI, tumor grade, or adjuvant therapy and recurrence among women who had HIR EC cancer (Supporting Table 1 ). MMR status and BMI were significantly associated with recurrence. After performing a backward selection process to obtain a final multivariable model, MMR status, BMI, receiving radiation treatment, and stage remained significant, and stage was still considered a confounder (Supporting Table 2 ). After controlling for BMI, stage, and receiving radiation therapy, the presence of dMMR (OR, 5.16; 95% CI, 2.10-12.69; P < .0005) was significantly associated with recurrence. Increasing BMI also was associated with a reduced odds of recurrence (BMI 30-35 kg/m 2 : OR, 0.41, BMI >35 kg/m 2 : OR, 0.24; P = .02). Although higher stage also was associated with an increased odds of recurrence (stage IB: OR, 2.12; stage II: OR, 5.58; P = .04), it was also a confounder of MMR status. The receipt of any form of adjuvant radiation therapy had a trend toward reduced odds of recurrence (OR, 0.42; 95% CI, 0.17-1.07; P = .06). In a univariable logistic regression model, the presence of dMMR also was associated significantly with distant recurrence (OR, 5.28; 95% CI, 1.56-17.86; P = .008,), but not with local recurrence.
Survival Analysis
RFS was significantly shorter in patients who had dMMR in Kaplan-Meier survival analysis (P = .001) (Fig. 1A) , with a 5-year RFS rate of 66% (Hall-Wellner 95% confidence band, 45%-79%) for those with dMMR versus 89% (Hall-Wellner 95% confidence band, 76%-94%) for those with iMMR. The 5-year OS rate was 74% versus 86% for the dMMR and iMMR groups, respectively; however, the difference was not significant (Supporting Fig. 1) .
In simple multivariable Cox proportional-hazards models that contained only MMR status and 1 other variable, age, the presence of LVSI, and tumor grade were not associated significantly with RFS among women who had HIR EC (Supporting Table 3 ). MMR status and BMI did have significant associations with RFS. After performing a backward selection process to obtain a final multivariable model, only MMR status and BMI remained significant (Supporting Table 4 ).
After controlling for BMI, the presence of dMMR (HR, 3.09; 95% CI, 1.53-6.23; P = .002) was associated significantly with reduced RFS. In addition, increasing BMI was significantly associated with improved RFS (BMI 30-35 kg/m 2 : HR, 0.45; BMI >35 kg/m 2 : OR, 0.28; P = .009).
There was a relatively high rate of patients who received no adjuvant therapy in this data set of women with HIR EECs. Because isolated vaginal recurrences can be prevented very effectively with VBT 15 and have a very high likelihood of salvage in the absence of prior radiation, [16] [17] [18] [19] [20] we also analyzed our data set excluding those patients who had an isolated vaginal recurrence. Twelve patients (18.8%) with dMMR and 6 (4.5%) with iMMR developed a distant and/or retroperitoneal/regional recurrence (OR, 4.88; P = .001). The 3-year RFS rate was 80.2% for patients who had dMMR compared with 96.6% for those who had iMMR, and the 5-year RFS rate was 73.5% versus 95%, respectively (P = .0004) (Fig. 1B) . The corresponding 5-year OS rate was 74% versus 86% for the dMMR and iMMR groups, respectively. We observed that RFS was significantly shorter in patients who had dMMR, when controlling for BMI in a multivariable analysis, with a 5-year RFS rate of 66% for those who had dMMR compared with 89% for those who had iMMR. In addition, traditional prognostic features, such as age, stage, grade, the presence of LVSI, and deep myometrial invasion, did not remain significant in the multivariable model, suggesting that the relative homogeneity of our patient population may have reduced some of the potential confounding of the association by these factors, because these factors already are incorporated in the HIR classification.
The correlations between MMR status and disease recurrence and survival in cancer have been extensively studied. Although dMMR has been associated with a better prognosis in CRC, its prognostic significance in EC is unclear. 21 Whereas many studies have reported worse survival and/or shorter disease-free survival among patients dMMR or microsatellite instability (MSI), 10, 14, [22] [23] [24] [25] other studies have demonstrated improved survival [26] [27] [28] [29] or no association. [30] [31] [32] [33] A recent meta-analysis also demonstrated no association between MMR status and OS or RFS. 34 These disparate results are likely because of the heterogeneous patient populations, including stage, different histologies (endometrioid and nonendometrioid), and adjuvant treatments within each study, as well as the differences in defining dMMR and/or MSI between studies. Similarly, the meta-analysis commented on the observed, marked interstudy heterogeneity. 34 Nonendometrioid types are more likely to recur distantly and are less likely have dMMR. Both of these factors may have negated the increased recurrence rate and worse survival observed in patients with dMMR, who are more likely to have endometrioid adenocarcinoma. 26, 32 In contrast, Stelloo and colleagues also studied a subset of women with HIR EEC from the PORTEC-1 and PORTEC-2 trials. dMMR was associated with an increased risk of locoregional and distant recurrence as well as a reduction in OS (HR, 2.319; 95% CI, 1.105-4.866; HR, 2.154; 95% CI, 1.022-4.540; and HR, 1.879; 95% CI, 1.307-2.700, respectively). 35 Both our current study and the study by Stelloo et al were restricted to patients who had EEC with HIR features, allowing for a relatively homogeneous patient population, eliminating the potential of confounders, and targeting the subgroup at highest need for improved treatment algorithms. Certain differences, such as increased "substantial LVSI" in the MSI group from the study by Stelloo et al, are likely explained by the slightly different criteria they used to select patients with HIR. For example, those authors considered only "substantial LVSI" as LVSI-positive and assigned patients to 4 separate categories (p53, POLE [polymerase ε], MSI, or no specific molecular profile), rather than iMMR or dMMR, as in our study.
Similar to other studies, 10, 14 grade and stage were significantly associated with MMR status, and the presence of deep myometrial invasion and LVSI demonstrated a trend toward an association with MMR status. Although these could be considered confounding factors, all patients in our study met HIR (GOG249) criteria. In this select population with a high clinical need for better treatment strategies, MMR status was able to identify those with the highest risk of recurrence. Therefore, as we transition to personalized medicine and aim to treat based on patient and tumor characteristics, identifying homogeneous subsets is critically important. The finding that other studies that included patients with HIR, such as GOG249 and PORTEC-3, were unable to demonstrate a significant survival difference and continued to report high percentages of distant recurrences despite pelvic radiation and/or systemic chemotherapy may be explained by a still-too-broad study population and suggests a need for biomarkers and a new treatment paradigm.
Our data indicated that, across all types of adjuvant therapy, the recurrence rate was higher among patients who had dMMR. We acknowledge that a relatively high percentage of patients received no adjuvant therapy in our HIR EEC data set. Because isolated vaginal recurrences can be prevented very effectively with VBT and have a very high likelihood of salvage in the absence of prior radiation, [16] [17] [18] [19] [20] we also analyzed our data set excluding patients who had an isolated vaginal recurrence. Even then, the recurrence rate was significantly higher for patients with dMMR (18.8% vs 4.5% for those with iMMR), with a corresponding decrease in 5-year RFS (73.5% vs 95%, respectively). This emphasizes that the difference in recurrence and RFS is not driven by (preventable) vaginal recurrences, but that MMR status can identify patients who are at risk for clinically significant recurrences. Combining this with the previously reported randomized trials in a similar population that had high distant recurrence rates despite receiving aggressive adjuvant treatment, 6 ,36 more effective therapy is urgently needed.
Recently, it was demonstrated that programmed cell death 1 (PD1) blockade with pembrolizumab produced significantly improved response rates and 20-week PFS among patients with CRC who had dMMR tumors compared with those who had MMR-proficient tumors. 37 In contrast, no responses were observed in the MMRproficient cohort. Two patients who had EC with MMR defects were included: 1 had a complete response, and 1 had a partial response (70% decrease), and the responses were durable. The results from a follow-up study
Cancer February 1, 2019 of the PD-1 inhibitor pembrolizumab in patients with recurrent dMMR EC have been encouraging, with a 56% overall response rate and a 89% clinical benefit rate. 38 Approximately 20% to 30% of primary ECs demonstrate some form of MMR defect, 39 and approximately 75% of these patients present at an early stage. Our current study demonstrates that MMR status can identify those patients at highest risk for distant recurrence, despite currently available adjuvant therapies. Whether these patients would potentially benefit from other novel therapies (eg, immunotherapy) deserves further study.
Previous studies have suggested that MMR status is associated with response to adjuvant therapy. Resnick and colleagues defined a subset of patients who had dMMR and nonendometrioid tumors, received radiation therapy, and demonstrated significantly improved OS and PFS compared with patients who had iMMR. 40 In addition, McMeekin et al reported improved PFS of borderline significance among patients with EEC in all stages who had probable MMR mutations and received treatment with adjuvant therapy. 10 Conversely, Bilbao et al reported significantly reduced disease-free survival in a small cohort of patients with stage I/II EEC who received radiation therapy. 41 In our study, we initially assessed the interaction between MMR status and either receiving radiation therapy and or receiving any form of adjuvant therapy, but neither was significant in either logistic regression models or Cox proportional-hazards models. However, the final multivariable logistic regression model did demonstrate reduced odds of recurrence with any form of radiation treatment, with borderline significance.
Our study was limited in the ability to detect differences according to adjuvant therapy and MMR status, because adjuvant therapy regimens were provided at the discretion of the treating physician and varied greatly, and the numbers in each adjuvant treatment group were relatively small. Even among only those with HIR EC, adjuvant therapy regimens included no adjuvant therapy, VBT only, EBRT only, chemotherapy only, or various combinations of radiation therapy and chemotherapy. This is a reflection of the treatment options in the National Comprehensive Cancer Network guidelines and also reflects the "real-world" variation between providers and institutions. From our data, we also note that many vaginal recurrences likely could have been prevented by vaginal or pelvic radiation, and VBT should strongly be considered for this population. 15 VBT has now been incorporated more routinely into our practice. In addition, this was a single-institution, retrospective study, and the possibility of selection bias cannot be excluded. Finally, it is well known that competing causes of death in patients with EC increase significantly with longer follow-up. 42 Unfortunately, we were only able to capture deaths from any cause, and competing causes of death may have led to a lack of difference in OS.
The strengths of our study include the relatively homogeneous patient population defined by HIR features as well as restriction to only pure endometrioid histology, which eliminated confounding variables. In addition, the long follow-up of approximately 54 months allowed for the adequate observation of recurrences and survival.
In summary, we have demonstrated that dMMR is associated with some traditional prognostic factors, including higher tumor grade and the presence of LVSI. In addition, the presence of dMMR in patients with HIR EC is highly associated with an increased odds of recurrence, a higher rate of distant recurrence, and decreased RFS, despite the receipt of similar adjuvant treatments across groups. MMR status not only can help identify patients with possible LS but also can serve as a readily available biomarker to identify which patients with HIR EEC are most likely to benefit from immunotherapy.
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